CONCISE GUIDANCE

ABSTRACT — Giant cell arteritis (GCA) or temporal arteritis (TA) with polymyalgia rheumatica (PMR) is among the most common reasons for long-term steroid prescription. GCA is a critically ischaemic disease, the most common form of vasculitis and should be treated as a medical emergency. Visual loss occurs in up to a fifth of patients, which may be preventable by prompt recognition and treatment. The British Society for Rheumatology (BSR) and the British Health Professionals in Rheumatology (BHPR) have recently published guidelines on the management of PMR. The purpose of this concise guidance is to draw attention to the full guidelines to encourage the prompt diagnosis and urgent management of GCA, with emphasis on the prevention of visual loss. They provide a framework for disease assessment, immediate treatment and referral to specialist care for management and monitoring of disease activity, complications and relapse.

KEY WORDS: diagnosis, giant cell arteritis, steroid therapy, treatment

Introduction

Giant cell arteritis (GCA) is the most common of all the vasculitides. Together with polymyalgia rheumatic, it represents one of the most common indications for long-term glucocorticosteroid therapy in the community. It is characterised by critical ischaemia at presentation and ranks among the common causes of acute blindness. Visual loss occurs in up to one-fifth of patients and this may relate to late recognition. Early recognition, referral and treatment are essential and GCA should be regarded as a medical emergency. However, it is subject to wide variations in clinical practice, as it is often managed in primary or in secondary care by general practitioners, rheumatologists, non-rheumatologists and ophthalmologists.

Aims of the guideline

The objective of this concise guidance is to produce a summary of the longer guidelines, and to improve the consistency of clinical practice by providing recommendations in the following areas:

• a prompt diagnostic, management and referral process for GCA
• appropriate advice on management of GCA with emphasis on prevention of vision loss with early recognition and prompt high-dose glucocorticosteroid therapy
• investigations (such as temporal artery biopsy) for disease diagnosis and assessment of severity, using clinical factors and histology
• appropriate advice on disease monitoring and treatment of relapses
• appropriate advice on bone protection and prevention of steroid side effects.

Information in this concise guidance has been extracted from the full guideline. Please refer to the full guideline for details of the methodology. The guidelines were developed using the AGREE format and Scottish Intercollegiate Guidelines Network guidance was used to grade the recommendations.

Early diagnosis

Early recognition and diagnosis of GCA is paramount. Common symptoms and signs are shown in Table 1, and criteria for diagnosis are shown in Box 1. Clinicians should remember that jaw and tongue claudication, visual symptoms, constitutional symptoms and acute phase response may go unrecognised especially if not accompanied by headaches. Patients at highest risk of neuro-ophthalmic complications do not always mount high inflammatory responses.

Temporal artery biopsy (TAB) is the cornerstone of diagnosis and often remains positive for two to six weeks after the commencement of treatment. A regular link with a local dedicated surgical unit experienced in TAB to support urgent referrals is recommended. However, TAB may be negative in some patients with GCA, due to the presence of skip lesions or to sub-optimal biopsy. Therefore, patients with negative biopsies should be managed as having GCA if there is a typical clinical and laboratory picture and response to steroids, typical findings on ultrasound, or neuro-ophthalmic features typical of GCA (eg anterior ischaemic optic neuritis).
Duplex ultrasonography can detect the characteristic appearance of a hypoechoic ‘halo’, occlusions and stenosis, but requires a high level of experience and training. Positron emission tomography scanning can pick up aortic and large vessel disease; and 3-tesla magnetic resonance imaging has shown mural enhancement in inflamed temporal and occipital arteries. These techniques show promise for the diagnosis and monitoring of GCA (particularly large vessel disease), but currently do not replace TAB for cranial GCA.

Treatment and complications of GCA

Prompt treatment with high-dose steroids is critical to reduce the likelihood of neuro-ophthalmic complications. The early complications are ischaemic deficits, such as vision loss and stroke. If one eye is affected there is high risk (20–50%) of bilateral vision loss with further delay or stoppage of treatment. Late complications include the development of aortic aneurysms.

The symptoms of GCA should respond rapidly to high-dose glucocorticosteroid treatment, followed by resolution of the inflammatory response. Failure to do so should raise the question of an alternative diagnosis. Steroid-related complications (eg weight gain, fractures, diabetes, hypertension, cataracts and bruising) are also common hence the importance of monitoring and titrating the dose down as soon as it is safe to do so. Low-dose aspirin has also been shown to decrease the rate of visual loss and cerebrovascular accidents in GCA.4 In recurrent or resistant GCA, methotrexate or other immunosuppressives (eg azathioprine or leflunomide) may be used as adjuvant therapy to allow reduction in the cumulative glucocorticosteroid dose, or a higher probability of glucocorticosteroid discontinuation without relapse.5

Implications and implementation

There are no cost implications for implementation of these guidelines apart from relevant training for general practitioners who should also have access to the routine investigations outlined and the ability to follow up as suggested. A referral pathway for GCA compatible with these guidelines is suggested in the Map of Medicine.

Further information on the guidelines, ie references, guideline development process, implications and implementation, is available.
The guidelines

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1 Early recognition and diagnosis</strong></td>
<td></td>
</tr>
<tr>
<td>• Clinicians should consider giant cell arteritis (GCA) in patients &gt;50 years presenting with the symptoms listed in Table 1.</td>
<td>C</td>
</tr>
<tr>
<td>• Particular attention should be paid to the predictive features of neuro-opthalmic complications which are:</td>
<td></td>
</tr>
<tr>
<td>‒ jaw claudication</td>
<td></td>
</tr>
<tr>
<td>‒ diplopia</td>
<td></td>
</tr>
<tr>
<td>‒ temporal artery abnormalities.</td>
<td></td>
</tr>
<tr>
<td><strong>2 Confirmation of diagnosis – temporal artery biopsy</strong></td>
<td></td>
</tr>
<tr>
<td>• Urgent referral for specialist opinion and temporal artery biopsy (TAB) should be considered whenever a diagnosis of GCA is suspected.</td>
<td>C</td>
</tr>
<tr>
<td><strong>3 Large vessel GCA</strong></td>
<td></td>
</tr>
<tr>
<td>• Large vessel GCA should be suspected in patients with prominent systemic symptoms, limb claudication or persistently high-inflammatory markers despite adequate glucocorticosteroid therapy.</td>
<td>C</td>
</tr>
<tr>
<td>• Imaging techniques, such as positron emission tomography and magnetic resonance imaging scanning, should be reserved for the assessment of suspected large vessel involvement.</td>
<td></td>
</tr>
<tr>
<td><strong>4 Initial corticosteroid therapy</strong></td>
<td></td>
</tr>
<tr>
<td>• High-dose glucocorticosteroid therapy should be initiated immediately when clinical suspicion of GCA is raised.</td>
<td>C</td>
</tr>
<tr>
<td>• Recommended starting dose regimens are shown in Table 2.</td>
<td></td>
</tr>
<tr>
<td>• To minimise the complications of steroid treatment:</td>
<td>A</td>
</tr>
<tr>
<td>‒ patients should also receive bone protection</td>
<td></td>
</tr>
<tr>
<td>‒ gastrointestinal protection should be considered.</td>
<td></td>
</tr>
<tr>
<td><strong>5 Glucocorticosteroid reduction</strong></td>
<td></td>
</tr>
<tr>
<td>• Steroid reduction should be considered only in the absence of clinical symptoms, signs and laboratory abnormalities suggestive of active disease.</td>
<td>C</td>
</tr>
<tr>
<td>• This should be balanced against the need to use the lowest effective dose, patient wishes and side-effects.</td>
<td></td>
</tr>
<tr>
<td>• Recommended dose reduction regimens are shown in Table 2.</td>
<td></td>
</tr>
<tr>
<td><strong>6 Use of low-dose aspirin</strong></td>
<td></td>
</tr>
<tr>
<td>• Should be considered in all patients with GCA, if no contra-indications exist.</td>
<td>C</td>
</tr>
<tr>
<td><strong>7 Monitoring of therapy</strong></td>
<td></td>
</tr>
<tr>
<td>• Patients should be monitored for evidence of relapse, disease-related and steroid-related complications.</td>
<td>C</td>
</tr>
<tr>
<td>• Monitoring should be clinical and supported by measurement of inflammatory markers. In particular the following features should be sought:</td>
<td></td>
</tr>
<tr>
<td>‒ headaches</td>
<td></td>
</tr>
<tr>
<td>‒ jaw and tongue claudication</td>
<td></td>
</tr>
<tr>
<td>‒ visual symptoms</td>
<td></td>
</tr>
<tr>
<td>‒ vascular claudication of limbs, bruits and asymmetrical pulses</td>
<td></td>
</tr>
<tr>
<td>‒ polymyalgic symptoms</td>
<td></td>
</tr>
<tr>
<td>‒ osteoporotic risk factors and fractures</td>
<td></td>
</tr>
<tr>
<td>‒ other glucocorticosteroid-related complications</td>
<td></td>
</tr>
<tr>
<td>‒ other symptoms that may suggest an alternative diagnosis.</td>
<td></td>
</tr>
<tr>
<td>• Recommendations for frequency of follow-up and investigation are shown in Table 2.</td>
<td></td>
</tr>
</tbody>
</table>
The guidelines – continued

8 Relapse
- Disease relapse should be suspected in patients with a return of symptoms of GCA, ischaemic complications, unexplained constitutional or polymyalgic symptoms. (Relapse is usually associated with a rise in erythrocyte sedimentation rate/C-reactive protein, but may occur with normal inflammatory markers.)
- All patients in whom relapse is suspected should be treated as shown in Table 2, and discussed or referred for specialist assessment.

9 Recurrent relapse
- Recurrent relapse or failure to wean glucocorticosteroid dose requires the consideration of adjuvant therapy, such as methotrexate or other immunosuppressants.
- These immunosuppressive agents should be started at the third relapse.

Fig 1. Pathway for management of giant cell arteritis (GCA).
### Starting dose regimens

**Uncomplicated GCA**
- No jaw/tongue claudication or visual symptoms:
  - prednisolone 40–60 mg (not less than 0.75 mg/kg) daily until resolution of symptoms and laboratory abnormalities.

**Complicated GCA**
- Evolving visual loss or history of amaurosis fugax:
  - intravenous methylprednisolone 500 mg to 1 g daily for three days before oral prednisolone.
- Established vision loss:
  - at least 60 mg oral prednisolone daily.

### Bone protection
- Weekly bisphosphonate and calcium/vitamin D supplementation

### Gastrointestinal protection
- Protein pump inhibitors (e.g., omeprazole, lansoprazole)

The dose may need adjustment, due to disease severity, co-morbid factors (e.g., diabetes, cardiorespiratory or renal disease), fracture risk, patient wishes, and adverse events. Some patients will require long-term low-dose glucocorticosteroid therapy.

### Dose reduction

**Standard regimen**
- 40–60 mg prednisolone (not less than 0.75 mg/kg) continued for four weeks (or until resolution of symptoms and lab abnormalities):
  - then dose is reduced by 10 mg every two weeks to 20 mg
  - then by 2.5 mg every two to four weeks to 10 mg
  - then by 1 mg every one to two months, provided there is no relapse.

**For enteric-coated prednisolone**
- As above down to 10 mg per day. For doses below this:
  - 10 mg/7.5 mg alternating for two months
  - then 7.5 mg daily for one to two months
  - then 7.5/5 mg alternating for one to two months
  - then 5 mg daily for one to two months etc.

Some patients may benefit from a more gradual glucocorticosteroid taper, or a period of treatment at a stable dose, such as 5 mg prednisolone for three months.

### Monitoring of treatment

**Frequency of follow-up**
- Weeks 0, 1, 3, 6 then months 3, 6, 9, 12 in the first year
- Extra unscheduled visits may be necessary in the event of relapse or adverse events.

**Investigations**
- **At each visit**
  - Full blood count, ESR/CRP, urea and electrolytes, glucose
- **Every two years**
  - Chest radiograph to monitor for aortic aneurysm (echocardiography, PET and MRI may also be appropriate)
  - Bone mineral density

**Treatment of relapse**
- **Headache only**
  - Treat with the previous higher glucocorticosteroid dosage
- **Headache and jaw claudication**
  - Treat with 40–60 mg daily prednisolone
- **Eye symptoms**
  - Treat with either 60 mg prednisolone or intravenous methylprednisolone
- **Large vessel GCA**
  - Investigate with imaging techniques (PET, MRI scanning)
  - Consider treatment using systemic vasculitis protocols

**CRP** = C-reactive protein; **ESR** = erythrocyte sedimentation rate; **GCA** = giant cell arteritis; **PET** = magnetic resonance imaging; **MRI** = magnetic resonance imaging; **PET** = positron emission tomography.

---

© Royal College of Physicians, 2010. All rights reserved.
Bhaskar Dasgupta

available at *Rheumatology* online with the full guidelines. An Arthritis Research Campaign booklet on GCA incorporating the guidelines will be published shortly. The booklet has been developed with recommendations from various patient representatives and members of patient organisations such as the Polymyalgia Rheumatica and Giant Cell Arteritis UK.

**References**


**Address for correspondence:** Professor B Dasgupta, Department of Rheumatology, Southend University Hospital, Prittlewell Chase, Westcliff-on-Sea, Essex SS0 ORY.

Email: bhaskar.dasgupta@southend.nhs.uk.

© Royal College of Physicians, 2010. All rights reserved.